Download pdf
Research on Consumption Points under the Background of New Technologies: An Industry Survey Analysis Based on the Biopharmaceutical Sector
- 1 Shanghai University of Finance and Economics, Shanghai City, 200433, China
* Author to whom correspondence should be addressed.
Abstract
The study of consumption points in the biopharmaceutical industry, using it as a case study, is an essential premise for ensuring the rapid development of new technologies. Based on an online survey of Chinese samples, this paper explores the relevant characteristics of micro-level individual consumption in the biopharmaceutical industry and analyzes the key factors behind it using a univariate linear regression model. The research findings suggest that most residents in China currently hold an optimistic attitude toward new biomedicine technologies, but have not yet used AI-based medical products or services. They are, however, willing to cautiously try AI-assisted medical products or services and believe that some products are overpriced, offering poor cost-performance ratios, which hinders their consumption of new technological products. More importantly, the study reveals that the impact of residents’ information on their experience with biomedicine and their knowledge reserves on biopharmaceutical consumption is positive and favorable.
Keywords
Biopharmaceuticals, New Technologies, Consumption Points, Linear Regression, China
[1]. Mao, J., Zhang, L., & Huang, S. (2024). The impact of tax incentives on technological innovation in biopharmaceutical companies: Empirical evidence from listed companies in the biopharmaceutical industry. Tax Research, 7, 128-135. https://doi.org/10.19376/j.cnki.cn11-1011/f.2024.07.022
[2]. Shen, J. (2024). Accelerating the improvement of China’s biopharmaceutical technological innovation policy system. China’s National Conditions and Strength, 2, 14-18. https://doi.org/10.13561/j.cnki.zggqgl.2024.02.004
[3]. Zheng, H., Li, S., Yang, Y., Xu, M., Shen, Y., & Wan, X. (2024). Current development trends and countermeasures of the biopharmaceutical application industry. Journal of Zhangzhou Vocational and Technical College, 1, 85-90. https://doi.org/10.13908/j.cnki.issn1673-1417.2024.01.0014
[4]. Jin, X., Yao, S., Feng, L., Li, W., Miao, X., He, W., & Yang, H. (2024). Comprehensive evaluation of the development of China’s biopharmaceutical industry and regional disparity analysis. Chinese Journal of Biotechnology, 5, 134-146. https://doi.org/10.13523/j.cb.2311057
[5]. Sheng, T., Jiang, R., & Shao, R. (2024). Policy text analysis of high-quality development of biopharmaceutical industries at the provincial (municipal) level from the perspective of policy tools. China New Drugs, 12, 1194-1200.
[6]. Wang, L., Yuan, Y., Mao, K., & Lu, J. (2023). Research on the evaluation of technological innovation capacity in the biopharmaceutical industry based on high-value patents. Chinese Journal of Biotechnology, 10, 120-128. https://doi.org/10.13523/j.cb.2303037
[7]. Zhang, L., & Su, J. (2021). Exploration of policy changes and governance characteristics in China’s biopharmaceutical industry. Chinese Health Economics, 6, 62-65.
[8]. Fang, F. (2021). Analysis of the consumption potential and growth points of Chinese residents: Based on the goal of realizing socialist modernization by 2035. Economic Dynamics, 2, 50-64.
[9]. Lu, Z., & Zheng, Z. (2016). The logical starting point, constraints, and path choices for cultivating new consumption growth points under the new economic normal. Economic Issues Exploration, 1, 1-6.
[10]. Wang, Y. (2020). Thoughts on advancing the development of new technology consumption in China. Economics and Management, 2, 1-6.
Cite this article
Chai,Y. (2025). Research on Consumption Points under the Background of New Technologies: An Industry Survey Analysis Based on the Biopharmaceutical Sector. Advances in Economics, Management and Political Sciences,172,41-48.
Data availability
The datasets used and/or analyzed during the current study will be available from the authors upon reasonable request.
Disclaimer/Publisher's Note
The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of EWA Publishing and/or the editor(s). EWA Publishing and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.
About volume
Volume title: Proceedings of the 4th International Conference on Business and Policy Studies
© 2024 by the author(s). Licensee EWA Publishing, Oxford, UK. This article is an open access article distributed under the terms and
conditions of the Creative Commons Attribution (CC BY) license. Authors who
publish this series agree to the following terms:
1. Authors retain copyright and grant the series right of first publication with the work simultaneously licensed under a Creative Commons
Attribution License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this
series.
2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the series's published
version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial
publication in this series.
3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and
during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See
Open access policy for details).